Crinetics Pharmaceuticals, Inc.
CRNX
$46.98
$1.974.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 143.00K | 1.03M | 361.00K | 0.00 | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 143.00K | 1.03M | 361.00K | 0.00 | -- |
| Cost of Revenue | 90.46M | 13.10M | 76.24M | 66.57M | 61.91M |
| Gross Profit | -90.32M | -12.07M | -75.88M | -66.57M | -61.91M |
| SG&A Expenses | 52.27M | 49.84M | 35.53M | 28.18M | 25.89M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 142.73M | 130.14M | 111.77M | 94.75M | 87.80M |
| Operating Income | -142.59M | -129.11M | -111.41M | -94.75M | -87.80M |
| Income Before Tax | -130.09M | -115.64M | -96.77M | -80.60M | -76.83M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -130.09M | -115.64M | -96.77M | -80.60M | -76.83M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -130.09M | -115.64M | -96.77M | -80.60M | -76.83M |
| EBIT | -142.59M | -129.11M | -111.41M | -94.75M | -87.80M |
| EBITDA | -141.57M | -128.15M | -110.48M | -93.96M | -87.03M |
| EPS Basic | -1.38 | -1.23 | -1.04 | -0.88 | -0.96 |
| Normalized Basic EPS | -0.86 | -0.77 | -0.65 | -0.55 | -0.60 |
| EPS Diluted | -1.38 | -1.23 | -1.04 | -0.88 | -0.96 |
| Normalized Diluted EPS | -0.86 | -0.77 | -0.65 | -0.55 | -0.60 |
| Average Basic Shares Outstanding | 94.22M | 93.79M | 93.10M | 91.49M | 80.09M |
| Average Diluted Shares Outstanding | 94.22M | 93.79M | 93.10M | 91.49M | 80.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |